DRMA vs DRTS

Dermata Therapeutics, Inc. vs Alpha Tau Medical Ltd. — Valuation Comparison 2026

DRMA

Biotechnology
Dermata Therapeutics, Inc.
Quality
2.8
out of 10
Value Trap
27
LOW
Price
$1.35
Last close
Models
7/13
Active
VS

DRTS

Biotechnology
Alpha Tau Medical Ltd.
Quality
2.3
out of 10
Value Trap
6
SAFE
Price
$10.13
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DRMA Fair ValueDRMA Upside DRTS Fair ValueDRTS Upside
Bayesian DCF Intrinsic $1.31 -3.2% $2.66 -73.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.26 -6.3% $0.44 -95.7%
PWERM Option-Based $1.53 +13.7% $10.17 -1.2%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRMA vs DRTS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRMA vs DRTS — Which Stock Is More Undervalued?

DRMA scores higher with a 2.8/10 quality rating vs DRTS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Dermata Therapeutics, Inc. (DRMA) and Alpha Tau Medical Ltd. (DRTS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRMA currently trades at $1.35 with a QOC of 2.8/10, while DRTS trades at $10.13 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).